Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy.
about
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistanceSuspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy.Biliary excretion of imatinib and its active metabolite CGP74588 during severe hepatic dysfunction.High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis.Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.Erlotinib and pantoprazole: a relevant interaction or not?Retrospective evaluation of methotrexate elimination when co-administered with proton pump inhibitorsRole of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors.Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: A retrospective cohort studyDrug interactions in childhood cancer.Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients.Preventing and Managing Toxicities of High-Dose MethotrexateThe Safety of Appropriate Use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus.Drug interactions in metastatic breast cancer.Pharmacokinetic drug-drug interactions with methotrexate in oncology.Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib.Adverse drug reactions due to drug-drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method.Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.Renal Drug Transporters and Drug Interactions.A Comparison of Alkaline Water and Mediterranean Diet vs Proton Pump Inhibition for Treatment of Laryngopharyngeal Reflux.Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia.Evaluation of para-Aminosalicylic Acid as a Substrate of Multiple Solute Carrier Uptake Transporters and Possible Drug Interactions with Nonsteroidal Anti-inflammatory Drugs In Vitro.Glucarpidase rescue in a patient with high-dose methotrexate-induced nephrotoxicity.High-dose methotrexate in adult oncology patients: a case-control study assessing the risk association between drug interactions and methotrexate toxicity.Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2.Clinical pharmacology in everyday clinical care.Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance.Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3.Drug Repositioning of Proton Pump Inhibitors for Enhanced Efficacy and Safety of Cancer Chemotherapy.Effects of Concomitant Medication Use on Gefitinib-Induced Hepatotoxicity.Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.The prognostic value of serum methotrexate area under curve in elderly primary CNS lymphoma patients.Lansoprazole Exacerbates Pemetrexed-Mediated Hematologic Toxicity by Competitive Inhibition of Renal Basolateral Human Organic Anion Transporter 3.
P2860
Q26865927-62D3C6F4-4033-4BBA-A4B4-2409C4879976Q33401038-6102B832-2B56-43B0-9D98-E39B920D9D43Q33557148-691F9FB3-2A8C-45DF-9BBC-D5240E6A4D8FQ33908105-4063F22E-6760-4E40-82E2-33D5C3C77582Q33909887-ED579440-4511-45C7-9232-B061BB0CD0F5Q34065294-6B458B27-F57C-4A66-9979-A6C449FE1E68Q34457467-2032541E-7D40-4FAF-BF2B-8457D5999557Q34571060-6F973865-0951-492C-B882-0E43F917F8FCQ34871636-483FF670-498B-4389-B288-B70760865564Q35913249-DBC8A73F-11A7-43DE-B159-28B4B7DB1A99Q36269700-138A323E-3944-429F-99AB-9A3188AEAF89Q36898141-D6060A71-AFF5-417F-A27D-1D47495C0919Q37373153-BFF7063F-33F0-47ED-B10A-1F605C07B5EBQ37496637-1FC6A22E-BC34-41D4-95DD-B14988747FF5Q37709906-0257C7FF-09A2-457C-9CAB-F7A3933311BEQ37791284-142CD899-0599-4C4D-A6FD-CAE54C5BCCCDQ37960131-A70CE716-4E8E-44C9-B789-FEC01AEDCADCQ38150978-AA762E23-772C-415A-8E46-F4F450803A48Q38658675-29AB64AC-F7BF-4499-B18F-F2BF746DBA17Q38865456-77AFF9F7-0435-4E8F-8116-203DC8CB453AQ39140289-E60C076F-4A88-43BA-B2BB-AA7BCD711003Q40053716-2F8AD392-66FC-4A73-A46B-5F9782D20F7DQ41404243-5B917D79-A000-44DF-BCFF-7AA5F5634A37Q42358808-3AB38E8F-2FF9-49A4-8CBE-AEA55C834259Q43260573-36EA4F81-0EAA-486C-97A9-D04099C7929AQ43924069-E6D6C4E5-DAE0-4D47-9386-018551E5DE02Q44639286-4D5C1FE8-A646-4707-8B82-EC777B27917FQ45142665-B22D0FD7-A5D9-4BD3-89FD-DD25A9F15027Q46446111-573D580D-B8A7-4136-8B72-EFE854FDC4A6Q47250639-82A7F206-FD1B-42FD-B366-A5C574F3DFC2Q48249474-931A89DF-098B-4087-BF1D-9756B144F7E6Q49215917-F596039B-C585-40B0-80E4-14CA4E978558Q49582579-7550FA94-73E2-44C4-94A3-CD3F997A26CAQ51012681-D4E384EA-5714-4118-BD3C-430F804EF302Q51350287-95978846-B480-4C21-B990-F26F55393DC2Q53052634-A1921080-F0E2-4401-9A55-5607B219742F
P2860
Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Co-administration of proton pu ...... igh-dose methotrexate therapy.
@en
Co-administration of proton pu ...... igh-dose methotrexate therapy.
@nl
type
label
Co-administration of proton pu ...... igh-dose methotrexate therapy.
@en
Co-administration of proton pu ...... igh-dose methotrexate therapy.
@nl
prefLabel
Co-administration of proton pu ...... igh-dose methotrexate therapy.
@en
Co-administration of proton pu ...... igh-dose methotrexate therapy.
@nl
P2093
P2860
P1476
Co-administration of proton pu ...... high-dose methotrexate therapy
@en
P2093
Hirofumi Tamaki
Kosuke Doki
Kunihiro Suzuki
Masato Homma
Satoko Hori
Yasufumi Sawada
Yukinao Kohda
P2860
P356
10.1111/J.1365-2125.2008.03303.X
P407
P577
2008-11-17T00:00:00Z